Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $455 Million
- Q2 2025
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 9,130,465 shares of DYN stock, worth $106 Million. This represents 19.12% of its overall portfolio holdings.
Number of Shares
9,130,465
Previous 9,130,465
-0.0%
Holding current value
$106 Million
Previous $95.5 Million
8.99%
% of portfolio
19.12%
Previous 27.97%
Shares
6 transactions
Others Institutions Holding DYN
# of Institutions
210Shares Held
123MCall Options Held
36.5KPut Options Held
16.7K-
Ra Capital Management, L.P. Boston, MA9.71MShares$113 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$110 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$88.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$85.8 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$63.5 Million14.09% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $602M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...